Heartflow, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
John C.M. Farquhar, Chief Executive Officer and a Director of Heartflow, Inc., sold 22,562 shares of common stock on August 10, 2026 for $28.31 per share.
NASDAQ
Marie L. Jones, Chief Accounting Officer of Heartflow, Inc., reported multiple transactions in common stock on March 6, 2026.
NASDAQ
Vikram Verghese, Chief Financial Officer of Heartflow, Inc., reported multiple transactions in common stock on March 6, 2026.
NASDAQ
Campbell Rogers, Chief Medical Officer of Heartflow, Inc., reported multiple transactions in common stock on August 6, 2026.
NASDAQ
John C.M. Farquhar, Chief Executive Officer and a Director of Heartflow, Inc., reported multiple transactions in common stock on August 6, 2026.
NASDAQ
John C.M. Farquhar, Chief Executive Officer and a Director of Heartflow, Inc., reported multiple transactions in common stock on July 30, 2026.
NASDAQ
Vikram Verghese, Chief Financial Officer of Heartflow, Inc., reported multiple transactions in common stock on July 27, 2026.
NASDAQ
Jeffrey C Lightcap, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 24, 2026.
NASDAQ
Timothy C Barabe, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 22, 2026.
NASDAQ
Vikram Verghese, Chief Financial Officer of Heartflow, Inc., reported multiple transactions in common stock on July 21, 2026.
NASDAQ
Timothy C Barabe, a Director of Heartflow, Inc., reported multiple transactions in common stock on July 17, 2026.
NASDAQ
Campbell Rogers, Chief Medical Officer of Heartflow, Inc., sold 9,219 shares of common stock on July 15, 2026 for $25.72 per share.
NASDAQ
John C.M. Farquhar, Chief Executive Officer and a Director of Heartflow, Inc., sold 22,562 shares of common stock on July 10, 2026 for $27.75 per share.
NASDAQ
Heartflow, Inc. Director William C. Weldon acquired 17,123 shares of common stock on July 8, 2026, through the exercise of stock options.
NASDAQ
Heartflow, Inc. CEO John Farquhar reported a transaction involving common stock, executed under a pre-arranged trading plan.
NASDAQ
Heartflow, Inc. director William C. Weldon acquired 16,075 stock options with an exercise price of $32.05, vesting in 2027.
NASDAQ
Heartflow, Inc. director Timothy C. Barabe acquired 16,075 stock options with an exercise price of $32.05, vesting in full by June 2027.
NASDAQ
Heartflow, Inc. Director Julie A. Cullivan reported the acquisition of stock options on June 16, 2026, as part of her compensation.
NASDAQ
Heartflow, Inc. director Jeffrey C. Lightcap acquired 16,075 stock options with an exercise price of $32.05.
NASDAQ
Heartflow, Inc. director Wayne Joseph Riley acquired 16,075 stock options at an exercise price of $32.05, with vesting scheduled for 2027.
NASDAQ
Heartflow, Inc. director Casey M. Tansey acquired 16,075 stock options with an exercise price of $32.05.
NASDAQ
Chief Medical Officer Campbell Rogers exercised 10,000 stock options at a price of $2.22 per share.
NASDAQ
Heartflow, Inc. CEO John C.M. Farquhar sold 22,562 shares of common stock at $28.50 per share.
NASDAQ
Chief Medical Officer Campbell Rogers exercised options and sold 9,219 shares of Heartflow, Inc. common stock.
NASDAQ
Heartflow, Inc. CEO John C.M. Farquhar sold 22,562 shares of common stock at $29.12 per share via a 10b5-1 plan.
NASDAQ
Chief Accounting Officer Marie L. Jones disposed of 567 shares of Heartflow, Inc. common stock to satisfy tax withholding obligations.
NASDAQ
Chief Medical Officer Campbell Rogers disposed of 2,271 shares of Heartflow, Inc. common stock to satisfy tax withholding obligations.
NASDAQ
Heartflow CFO Vikram Verghese disposed of 2,009 shares to satisfy tax obligations related to restricted stock unit vesting.
NASDAQ
CEO John Farquhar disposed of 7,204 shares of Heartflow common stock to satisfy tax obligations related to RSU vesting.
NASDAQ
Bain Capital Life Sciences has reduced its stake in Heartflow, Inc. through a series of open market sales totaling approximately 1.99 million shares.